Tsutsui T, Tsutamoto T, Maeda K, Kinoshita M
First Department of Internal Medicine, Shiga University of Medical Science, Otsu, Japan.
J Cardiovasc Pharmacol. 2001 Oct;38 Suppl 1:S81-5. doi: 10.1097/00005344-200110001-00017.
We evaluated the comparative effects of furosemide, a short-acting loop diuretic, and azosemide, a long-acting loop diuretic, on neurohumoral factors and quality of life (QOL) in patients with congestive heart failure (CHF). Twenty-five stable patients with mild chronic CHF who had been administered furosemide (n = 14) or azosemide (n = 11) orally for more than 3 months were studied. We changed furosemide to azosemide or azosemide to furosemide and followed for 3 months. Echocardiography was performed, and we also measured neurohumoral factors and assessed QOL by questionnaire. Blood pressure, body weight, renal function and echocardiographic findings were the same during the furosemide and azosemide treatments. Plasma levels of atrial natriuretic peptide and brain natriuretic peptide were not different between the two treatments. However, plasma concentrations of active renin and norepinephrine were significantly higher with furosemide treatment than with azosemide treatment. QOL score was significantly lower with azosemide than with furosemide. These findings suggest that long-acting loop diuretics may have fewer adverse effects on the neuroendocrine system and QOL than short-acting loop diuretics in patients with mild CHF.
我们评估了短效襻利尿剂呋塞米和长效襻利尿剂阿佐塞米对充血性心力衰竭(CHF)患者神经体液因子和生活质量(QOL)的比较影响。研究对象为25例稳定的轻度慢性CHF患者,他们口服呋塞米(n = 14)或阿佐塞米(n = 11)超过3个月。我们将呋塞米换为阿佐塞米或阿佐塞米换为呋塞米,并随访3个月。进行了超声心动图检查,我们还测量了神经体液因子并通过问卷调查评估了生活质量。在呋塞米和阿佐塞米治疗期间,血压、体重、肾功能和超声心动图检查结果相同。两种治疗之间心房利钠肽和脑利钠肽的血浆水平无差异。然而,呋塞米治疗组的活性肾素和去甲肾上腺素血浆浓度显著高于阿佐塞米治疗组。阿佐塞米治疗组的生活质量评分显著低于呋塞米治疗组。这些发现表明,在轻度CHF患者中,长效襻利尿剂对神经内分泌系统和生活质量的不良影响可能比短效襻利尿剂少。